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Abstract  
Objectives: This paper estimates productivity loss using the health of the patient in order to allow 
indirect estimation of these costs for inclusion in economic evaluation.  
Methods: Data were used from two surveys of inpatients (HODaR sample n=42,442 and HIPO sample 
n= 6,046). The number of days off paid employment or normal activities excluding paid employment 
was modelled using the health of the patients measured by EQ-5D, International Classification of 
Diseases (ICD) chapter and other health and sociodemographic data. Two part models (TPM) and 
zero inflated negative binomial (ZINB) models were identified as the most appropriate specifications 
given large spikes at the minimum and maximum days for the dependent variable. Analysis was 
undertaken separately for the two datasets to account for differences in recall period and 
identification of those who were employed. 
Results: Models were able to reflect the large spike at the minimum (zero days) but not the 
maximum with TPM doing slightly better than the ZINB model. EQ-5D was negatively associated with 
days off employment and normal activities in both data sets but ICD chapters only had statistically 
significant coefficients for some chapters in HODaR.  
Conclusions: TPM can be used to predict productivity loss associated with the health of the patient 
to inform economic evaluation. Limitations include recall and response bias and identification of 
who is employed in HODaR while HIPO suffers from small sample size. Both samples exclude some 
patient groups.  
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Key points for Decision Makers: 
x Productivity losses are important indirect costs of poor health and they can be estimated 
from the health of the patient 
x Models based on EQ-5D and diagnosis using the international classification of diseases (ICD) 
can be used to predict productivity loss including time off work and time off unpaid activities 
x Estimates can be included in economic evaluation where productivity has not been 
measured directly 
1 INTRODUCTION 
 
Economic evaluation combines information on costs and benefits to inform priority setting in health 
care and to inform decisions on the reimbursement of health care interventions. Costs are typically 
the direct costs of providing health care but where a societal perspective is taken, then outcomes 
ďĞǇŽŶĚƚŚĞƉĂƚŝĞŶƚƐ ?ŚĞĂůƚŚĂŶĚĚŝƌĞĐƚĐŽƐƚƐŽĨŚĞĂůƚŚĐĂƌĞƐŚŽƵůĚďĞƚĂŬĞŶŝŶƚŽĂĐĐŽƵŶƚ[1].  
 
Productivity refers to the economic output associated with both paid and unpaid work. The health of 
patients impacts upon their ability to work, often resulting in either having to take time off work 
(absenteeism) or returning to work at reduced capacity causing productivity losses (presenteeism) 
[2]. In the United Kingdom (UK), days off paid employment due to ill-health are estimated to be 140 
million working days per year with costs to employers valued at £9 billion while the government 
spends £13 billion on health-related welfare payments [3]. The inclusion of productivity costs can 
have a substantial impact on the results of an economic evaluation [4] and these costs therefore 
warrant consideration. The exclusion of productivity costs has often been justified based on 
supporting decision makers in the health sector whose objective is to maximise health therefore 
non-health costs and outcomes need not be considered.  However, it can be argued that exclusion of 
the wider economic costs and outcomes can lead to suboptimal resource allocation. From a welfarist 
perspective, inclusion of all costs and outcomes in economic evaluation would be the recommended 
approach where the objective is to maximise social welfare [5]. A societal perspective may also be 
ƉƌĞĨĞƌƌĞĚĂƐŝƚƌĞĨůĞĐƚƐĚĞĐŝƐŝŽŶŵĂŬŝŶŐƵŶĚĞƌĂ ‘ǀĞŝůŽĨŝŐŶŽƌĂŶĐĞ ?ǁŚŝĐŚǁŽƵld be more acceptable 
to members of the public who are not aware of which conditions will affect them in the future and 
therefore where the costs would fall [6].  
 
Productivity loss is typically measured using time-off paid employment, time-off unpaid 
employment, or time-off usual activities due to ill health. For absenteeism, this can be self-reported 
by patients or objective data reported by employers [2]. Questionnaires such as the Health Labour 
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Questionnaire [7] have been developed to ask about time-off work or away from unpaid work over a 
specific period e.g. the last 7 or 14 days.  However, it can be difficult for respondents to separate 
leisure from unpaid work and an alternative approach focusing on the time spent by others doing 
the work of the person who is ill has been advocated to minimise this problem [5]. Some 
productivity loss questionnaires also include questions to measure presenteeism. However, where 
questions related to productivity have not been asked, estimating productivity loss may not be 
possible. 
 
A potential solution to estimating productivity losses where productivity questions have not been 
asked is to predict them indirectly using health related quality of life (HRQoL) measures used in cost 
utility analysis such as EQ-5D. Brouwer et al [8] present a theoretical model of a U shaped 
relationship between productivity loss and HRQoL which included periods of presenteeism before 
and after a period of absenteeism. Empirical studies support this relationship with associations 
found between productivity loss and EQ-5D including Lamers, et al. [9]  in patients with lower back 
pain and Bouwmans et al [10] in patients with depression and anxiety for absenteeism while 
Kawalec and Malinowski [11] found a negative association between EQ-5D and presenteeism in 
patients with ankylosing spondylitis.  Krol, et al. [12] used a representative general population Dutch 
sample to collect data on EQ-5D and productivity in order to develop models to predict productivity 
indirectly. Their results showed good external validity although they were not based on actual time-
off paid employment but rather on hypothetical estimates made by the respondents on whether 
they would go to work given a particular EQ-5D state.  Bouwmans et al [10] found differences in the 
relationship based on whether patients had anxiety, depression or both indicating that disease 
status may be important. 
 
The aim of this current study was to model the relationship between EQ-5D and productivity using a 
large mixed patient sample in order to allow for indirect estimation of productivity losses for 
inclusion in economic evaluation.   
2 METHODS 
2.1 Data 
This study uses two alternative UK patient datasets: Health Outcomes Data Repository (HODaR) and 
Health Improvement and Patient Outcomes (HIPO). Both datasets were from inpatients attending 
Cardiff and Vale NHS Hospitals Trust, a large University hospital in South Wales, UK. HODaR covers 
the period between 2002 and January 2009 [13] while HIPO data were restricted to 2014.   
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The same data collection methodology was used in both datasets. Surveys were sent six weeks after 
discharge to all subjects aged 18 years or older.  People with a primary diagnosis of a psychological 
illness or learning disability on admission were excluded. The survey was linked to existing routine 
hospital health data to provide a dataset with socio-demographic, HRQoL and diagnosis data 
provided without any personal identifiers. Informed consent was obtained from survey participants. 
Both surveys were reviewed by ethics committees (Bro Taf Local REC 02/4685 and NRES Committee 
North West Chester 12/NW/0535). 
 
HODaR reported employment status but this did not include whether the respondent was retired.  
Those who said they were employed or self-employed and aged 65 and under (pre-retirement age) 
were selected to represent the employed group in HODaR. The HIPO questionnaire was designed to 
ensure that employment status included  ‘retired ? as a separate option. 
 
2.2 Measures 
Survey respondents were asked two single item questions about employment and normal activities: 
 ?,ŽǁŵĂŶǇĚĂǇƐŽĨĨŚĂǀĞǇŽƵŚĂĚƚŽƚĂŬĞŽĨĨƉĂŝĚĞŵƉůŽǇŵĞŶƚĚƵĞƚŽǇŽƵƌŚĞĂůƚŚ ? ? ?ĂŶĚ ?KƚŚĞƌ
than paid employment, how many days have you had to spend away from your normal activities, 
Ğ ?Ő ?ŐĂƌĚĞŶŝŶŐ ?ŚŽƵƐĞǁŽƌŬ ?ĚƵĞƚŽǇŽƵƌŚĞĂůƚŚ ?? ?. Recall was 6 weeks in HODaR and 4 weeks (paid 
employment) and 1 week (normal activities) in HIPO.  The revised recall period used in HIPO was 
designed to reduce recall bias and so that health as measured by the EQ-5D (which relates to health 
 ‘ƚŽĚĂǇ ? ?ǁŽƵůĚďĞŵŽƌĞĐůŽƐĞůǇĂůŝŐŶĞĚƚŽƚŚĞŚĞĂůƚŚĞǆƉƌŝĞŶĐĞĚĚƵƌŝŶŐƚŚĞƌĞĐĂůůƉĞƌŝŽĚ ? 
 
Health was measured using the self-reported EQ-5D as well as primary diagnosis based on the 
International Classification of Diseases (ICD). EQ-5D is a preference-based HRQoL measure which has 
five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. There 
are two versions: the 3 level version which has three severity levels (no/moderate and severe 
problems) for each dimension and the more recently developed 5 level version (includes mild and 
ĞǆƚƌĞŵĞ ?ďŽƚŚǁŝƚŚĂƌĞĐĂůůƉĞƌŝŽĚĨŽƌ ‘ƚŽĚĂǇ ? [14;15]. The 3-level version has utility values elicited 
from the general population that range from -0.594 to 1, [16] and the cross-walk algorithm was used 
to generate EQ-5D-3L utility values using the same valuation survey for the EQ-5D-5L [17]. HODaR 
used EQ-5D-3L while HIPO used EQ-5D-5L. The EQ-5D is the recommended HRQoL measure for 
health technology assessment (HTA) in England [18] and is widely used. It is therefore useful to use it 
as the basis of linking health to productivity losses. 
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ICD 10
th
 version (ICD-10) [19] was used to record clinical diagnosis in the hospital. ICD classifications 
were recorded as primary diagnosis (reason for admission) as well as for secondary diagnoses in the 
hospital data and these were linked to survey data along with routine data on surgical procedures.  
 
2.3 Analysis 
Descriptive statistics of sample characteristics across the samples used to estimate productivity 
losses were generated. Spearman rank correlation between days off work/normal activities and EQ-
5D was assessed. Regression analysis was used to estimate the relationship between HRQoL of the 
patient and days off paid employment due to illness and days off normal activities. 
 
2.3.1.1 Explanatory variables 
The main explanatory variables included EQ-5D utility score and ICD categories. Dummy variables 
were used to represent the different ICD groups with Chapter 21 (factors influencing health status 
and contact with health services) excluded as the reference, presence of comorbidities (at least one 
secondary diagnosis) and for surgical procedures (operation) during their most recent 
hospitalisation. Gender and age were also added to the models as these can be related to 
productivity.  
 
2.3.1.2 Dependent variables  
The dependent variables were days off paid employment or days off normal activities which are 
count data. In HODaR, although the 6-week recall period gave a maximum of 42 days some 
respondents reported up to 45 days; these were recoded to 42.  In HIPO, the recall period was 4 
weeks (maximum 28 days) for days off paid employment or 1 week for days off normal activities. 
Very few respondents (1.8%) reported over 20 days in HIPO so days above this number were 
recoded to 20.  There was a large proportion of respondents in both datasets who reported zero 
days off paid employment or zero days off normal activities. The spike at zero is usual in this type of 
data and is a reflection of the large number of people who do not need to take any days off. There 
were also spikes at the maximum number of days as well as smaller spikes at multiples of 5 and 7 
days which potentially reflects a number of issues, including measurement errors and real 
phenomena.  For example, when answering the question, people may have used a heuristic based 
that was based on calendar weeks or working weeks.  Alternatively, it may reflect individuals 
rounding off responses or due to behavioural factors that result in individuals taking whole, rather 
than partial, weeks off work when ill.   
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2.3.1.3 Models 
Different count models can be used to assess the relationship between productivity and health. In a 
study examining the effect of health on informal care time, Rowen et al [20] compared Poisson, 
negative binomial, two-part and zero-inflated negative binomial models where the explanatory 
variable was the number of days receiving care. That study showed that the two part model and 
zero-inflated negative binomial models outperformed the others.  The distribution for the number of 
days receiving care was similar to the number of days off paid work with a large spike at zero  and 
the maximum number of days and positively skewed data.  Therefore, we focus on models able to 
deal with these two characteristics: two-part models (also known in the literature as hurdle models) 
and zero inflated models. The distribution for positive counts was positively skewed with a long tail 
and the variance exceeded the mean which was evidence of overdispersion and in parallel to the 
Rowen study, we use negative binomial specifications for both. 
 
Both the two-part models (TPM) and zero-inflated negative binomial (ZINB) are similar in that they 
can generate a large number of zeros. They differ, however, in the way those zeros are generated. 
The TPM assumes that the zeros and the positive outcomes are generated by two completely 
different processes, zeros are a hurdle to overcome before positive counts can be attained. The ZINB 
assumes that the zeros can be the outcome of two processes due to two different groups of 
individuals. One group will always have a count of zero, never a positive count, the second group 
might happen to have a zero count but there is a positive probability that s/he could have a positive 
count.  
 
The TPM in this paper combines a binary probit model to predict the zeros with a zero truncated 
negative binomial regression for the positive counts defined by the following two equations: 
 
    けzz '|0Pr iiiy )   (1a) 
 
and 
 
      DD /1'11 |Pr,0|Pr  ! くxxx ieyyy iiiii  
(1b) 
 
where iz is a vector of random variables which determine the probability of a zero in the data, け  is 
the corresponding parameter vector and  iiy x|Pr  is: 
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where  * is the gamma function and D is the degree of dispersion. The vector iz  could in 
principle be identical to ix .  
 
The expected counts for the TPM are found using the formula below: 
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The ZINB models can be estimated using either constant inflation or allowing inflation to be a 
function of explanatory variables. The zero-inflated negative binomial model can be defined by the 
negative binomial in equation (4): 
 
  iii [K  くx'exp  (4) 
 
together with a logit model for the probability of group membership: 
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The expected counts for the model are found using the formula below: 
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The models were assessed to identify which fitted the data best based on the predictive 
performance of the models as well as Akaike Information Criterion (AIC) [21] and the Schwarz 
Bayesian Information Criterion (BIC) [22]. To aid interpretation, marginal effects for the models are 
reported and the model coefficients are reported in the Appendix. STATA version 12 was used for all 
the statistical analyses. 
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3 RESULTS 
3.1 Descriptive statistics 
Mean EQ-5D utility scores were higher for those were aged 65 and under who were employed in 
both samples (0.730 and 0.795 in HODaR and HIPO respectively) compared to the full sample (Table 
1). Mean age for employed respondents was lower than for the full samples (48.6 vs. 58.2 and 49.0 
vs. 60.3 for HODaR and HIPO respectively). Around 50% of the samples were female and a majority 
had a comorbidity and operation (Table 1). Mean length of stay ranged from 1.5 days in HIPO to 4.5 
days in HODaR. However, despite selection based on being an inpatient, a large proportion (43% in 
HODaR and 57% in HIPO) had less than a day stay in hospital. Across the samples, the largest ICD 
Chapters included those for neoplasms, diseases of the circulatory, digestive, musculoskeletal and 
genitourinary systems and systems not classified elsewhere (Table 1).  
 
[Insert Table 1] 
 
Mean number of days off work was 8.5 in HODaR and 9.10 in HIPO while mean days off normal 
activities was 4.8 and 1.1 respectively across the two samples (Table 2). Majority reported 0 days off 
work and normal activities (Table 2).  In HODaR, there was a weak negative correlation between 
days off paid employment and EQ-5D score (rho=-0.1222 p<0.001) compared to -0.3866 p<0.001 in 
HIPO.  There was little variation in mean days off paid employment for those with EQ-5D scores less 
than 1 in HODaR whereas in HIPO, mean days off paid employment fell as EQ-5D scores increased 
(Table 2). The correlation between EQ-5D scores and days off normal activities was stronger in 
HODaR (rho=-0.3668 p<0.001) with similar results in HIPO (rho=-0.3378 p<0.001). Mean days off 
normal activities based on EQ-5D score reflected these correlations in HODaR but slightly less so in 
HIPO (Table 2).  
 
[Insert Table 2] 
 
3.2 Regression results 
3.2.1 Days off paid employment  
AIC and BIC indicated that the ZINB with variable inflation (HoDAR: AIC=121,875 BIC=122,129; HIPO 
AIC=7,887 BIC=8,043) were slightly better than the ZINB with constant inflation (HoDAR: AIC 123,654 
BIC=123,876; HIPO AIC=8,110 BIC=8,244) so only the former models are reported. In both HODaR 
and HIPO, the two-part model (TPM) and zero-inflated negative binomial (ZINB) model predicted the 
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spike at zero well for days off paid employment (Figure 1). The other spike was at the maximum (42 
and 20 days respectively) which was under-predicted. The TPM did slightly better at predicting the 
maximum number of days off paid employment but this was still below the observed maximum 
number. The models either over-predicted or under-predicted the number of days off for the 
number of days off paid employment greater than zero but less than the maximum (Figure 1).  
 
[Insert Figure 1] 
 
In HODaR, Chapters 2 (neoplasms), 5 (mental health), 6 (nervous system), 9 (circulatory system), 13 
(musculoskeletal), 17 (congenital malformations), and 19 (injury, poisoning external causes) were 
statistically significant at the 10% level and associated with more days off paid employment than 
Chapter 21 (Table 3). Chapters 3 (diseases of the blood), 12 (skin and subcutaneous tissue) and 18 
(symptoms not classified elsewhere) were statistically significant and associated with fewer days off 
paid employment compared to Chapter 21 (Table 3).   
 
In contrast, very few of the ICD coefficients were statistically significant in HIPO with the exception 
being in the first part of the TPM (Table 3). Only coefficients for Chapters 3 (blood) and 8 (ear and 
mastoid) in HIPO were statistically significant for part 2 of the TPM and in the ZINB model but 
coefficients were larger compared to coefficients for other variables and may reflect the small 
samples for the ICD chapters (n = 20 and 19 respectively). Coefficients for ICD chapters in HIPO 
generally had the same sign as those in HODaR but the number of days off associated with each 
Chapter varied by sample which is expected given the different recall periods (Table 3). 
 
Higher EQ-5D scores were associated with fewer days off paid employment in both HODaR and HIPO 
with a unit increase in EQ-5D resulting in reduced days off work of 7 to 14 days depending on the 
sample and model (Table 3). Increasing age was associated with more days off paid employment 
(and a lower probability of reporting zero days off paid employment) and this was at a decreasing 
(increasing) rate (Table 3). Being female was associated with fewer days off paid employment while 
having a comorbidity was associated with more days off in HODaR while in HIPO these were not 
statistically significant apart from in the first part of the TPM (Table 3). Having an operation was 
associated with more days off paid employment in HIPO but not HODaR. In the ZINB models, both 
the constant and variables (EQ-5D, age and female) are statistically significant in HODaR but age is 
not statistically significant in HIPO. There were also differences in coefficient direction for the 
constant and female inflation variables in the two samples (Appendix Table 5).  
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[Insert Table 3] 
 
3.2.2 Days off normal activities 
As with the days off paid employment regressions, the ZINB with variable inflation regressions 
(HoDAR: AIC=261,909 BIC=262,186; HIPO AIC=12,841 BIC=13,028) were preferred to the ZINB with 
constant inflation (HoDAR: AIC=267,396 BIC=267,637; HIPO AIC=13,434 BIC=13,595) so the latter 
models are not reported. Predicted days off normal activities showed a similar pattern to days off 
paid employment in HODaR. The TPM and ZINB model predicted the spike at zero reasonably well 
but under-predicted the spike at 42 days (Figure 2). There was also under and over-prediction for 
days off normal activities greater than zero but less than the maximum. In HIPO, prediction of the 
spike at zero was also good for both the models. However, the TPM predicted the spike at 7 days 
well (7.18 vs observed of 8.6). Although this was better than the ZINB model, overall there was over-
prediction in the TPM compared to observed days off normal activities.  
 
[Insert Figure 2] 
 
 
There were more ICD chapters that were statistically significant in HODaR compared to HIPO in the 
days off normal activities regressions with some similarities with which ICD chapters were 
statistically significant with Chapters 2, 5, 9, 13, 17, and 19 along with Chapter 10 (respiratory 
system) associated with more days off normal activities than Chapter 21 in HODaR (Table 4). In 
addition, Chapter 7 (eye and adnexa) and 15 (pregnancy and childbirth) were associated with fewer 
days off normal activities in HODaR. The number of days off normal activities associated with each 
ICD chapter was generally less than the number of days off paid employment apart from for Chapter 
15 (pregnancy) and 17 (congenital mal/deformations).  In HIPO, only Chapter 11 (digestive system) 
was statistically significant and the number of days was less than 1 for all the ICD chapters.  
Higher EQ-5D scores were associated with fewer days off normal activities in both samples (Table 4), 
and this is the key parameter of interest. Age was statistically significant and positive but age 
squared was also positive in the ZINB model indicating that days off normal activities increased at a 
higher rate as age increased. Having a comorbidity was associated with fewer days off normal 
activities in the ZINB model in contrast to more days off as seen for paid employment in HODaR.  The 
inflation variables in HODaR and HIPO were statistically significant (Appendix Table 6).    
[Insert Table 4] 
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4 DISCUSSION 
This paper presents regression analyses that enable the estimation of productivity losses associated 
with the health of the patient. Such an approach enables productivity loss data to be estimated 
indirectly for individual economic evaluations, by allowing estimates to be derived from EQ-5D data.  
 
In terms of predictive performance, there was little to choose from between the TPM and ZINB but 
the TPM did slightly better than the ZINB when considering the prediction of the maximum days off 
either paid employment or normal activities therefore this model is recommended for use. The 
coefficients for the recommended models are reported in Appendix Table 7. The choice of which 
sample to use should be informed by the sample where results will be applied although both data 
sets used in the analysis have limitations which are highlighted later in the discussion.  
 
Further external validation is recommended to ascertain whether the TPM would work as well in 
other samples. This is important as at the aggregate, the models used to estimate productivity loss 
were able to accurately predict the spike at zero but under-predicted the number of days off at the 
maximum in both samples. The only exception was predictions of days off normal activities in HIPO, 
the smaller sample. However, these predictions were associated with errors of overall over-
prediction which would be amplified out-of-sample.  
 
The relationship between EQ-5D and productivity losses was consistent and significant, where lower 
EQ-5D score meant higher productivity losses. This result is broadly similar to that reported by Krol, 
et al. [12] although models were different. There were some differences in the coefficient sizes 
particularly for paid employment in the ZINB variable inflation models. This may reflect differences 
in sample size and/or recall period. Some ICD chapters had statistically significant associations with 
productivity mainly in HODaR. Compared to the Krol et al. [12] model, the results presented here are 
based on real data and also account for different diseases as well as characteristics such as the 
presence of a comorbidity or whether respondents have had an operation which can be considered 
to have an impact on absenteeism. Furthermore, the results can also be used to predict days off 
normal activities in addition to days off work.  
 
The results presented here enable productivity loss to be estimated using available data, yet it 
should be recognised that these are only predictions and are unlikely to be as accurate as collecting 
productivity data directly from respondents in studies. However one advantage of this technique is 
that productivity loss can be estimated for studies retrospectively where this information was not 
collected. A further advantage is that the same methodology can be used to produce comparable 
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estimates of productivity loss for all studies involving EQ-5D. These comparable estimates can then 
be used to inform economic evaluation. 
 
4.1 Limitations 
This study used EQ-5D score as the independent variable relating to health, in order that the results 
could be applied to data that are commonly reported in economic evaluations. However, the 
correlations between EQ-5D and days off work/normal activities were weak to moderate. This is a 
limitation to the approach where EQ-5D is the key parameter of interest but this was not the only 
parameter included in the models and overall the models had good predictive performance apart 
from the maximum number of days off. Under-prediction would under-estimate the level of 
productivity loss but this is likely to be for a small sub-sample (10% or less) based on the datasets 
used in this analysis. 
 
Although HODaR and HIPO data provided a large sample of patients with different conditions, there 
were limitations associated with these samples. Some conditions based on ICD codes had very small 
groups which may limit applicability of results in these groups. Furthermore, the datasets did not 
include patients with a primary diagnosis on admission of a psychological illness or learning 
disability, and therefore these estimates are not recommended for use in health interventions for 
these patients. The analysis was based on patients who had been recently hospitalised and they may 
be significantly different from other patient populations  In addition all data was collected in the UK 
and hence may not be representative in countries with different payment compensation schemes 
for days off work. Therefore the results may not be generalisable. While EQ-5D has been used for all 
patients, it may not be an appropriate measure of health for all patient groups and estimating 
productivity losses using EQ-5D data would also be inappropriate.   
 
A further related limitation of using the HODaR data is that retired individuals reported past 
employment which was addressed by excluding those who are above retirement age but this may 
not have captured everyone. Mean age for those who were employed in HODaR and HIPO was 48.6 
and 49.0 and EQ-5D scores were 0.730 and 0.795 in HODaR and HIPO respectively (note use of EQ-
5D-3L in HODaR and EQ-5D-5L cross-walked to 3L in HIPO) which may indicate that the selected 
 ‘ĞŵƉůŽǇĞĚ ? ƐĂŵƉůĞ ŝŶ ,KĂZ ǁĂƐ ĐŽŵƉĂƌĂďůĞ ŝŶ ƚĞƌŵƐ ŽĨ ĂŐĞ ĂŶĚ ŚĞĂůƚŚ ? ,ŽǁĞǀĞƌ ? ĂƐ ŶŽƚĞĚ ?
correlation between health and days off paid employment was weak in HODaR which suggests that 
although summary statistics were similar, there was more variation in HODaR which may be as a 
ƌĞƐƵůƚŽĨŝŶĚŝǀŝĚƵĂůƐŝŶƚŚĞ ‘ĞŵƉůŽǇĞĚ ?ƐĂŵƉůĞǁŚŽǁĞƌĞŶŽƚĞŵƉůŽǇĞĚ ? 
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The spikes in the data where full weeks have been counted e.g. 7, 14 etc. indicate that respondents 
were rounding off days which may indicate some form of recall bias although it may also reflect the 
number of days that patients are signed-off from work. In the literature recommended recall periods 
of 3 months for productivity have been suggested [2]  but the evidence in HODaR suggests that there 
is some bias over a longer period.  In addition HIPO finds less evidence of a spike at the maximum 
days off paid employment. However, shortening the recall period in HIPO may have resulted in 
under-estimation of the number of days off work as it may have excluded the period immediately 
after discharge.  
 
While this study provides a means to estimate the productivity losses associated with HRQoL in 
terms of predictions of days, the valuation of these losses can be challenging where there is no 
information on the type of work or usual activities which have not been undertaken.  In addition, 
whilst our study did include productivity losses outside paid employment, our productivity losses did 
not include presenteeism.  Estimating these effects would require additional data collection. 
 
Finally, this study used EQ-5D utility scores to enable productivity losses to be estimated. However, 
better specified relationships may be possible by using responses to the individual EQ-5D questions.  
Dixon et al [23] used this approach when examining the impact of EQ-5D responses on carer time 
and found that those models outperformed those using EQ-5D scores as the independent health 
variable.  This may suggest that whilst the use of the EQ-5D score is a convenient approach to 
estimating production losses, more accurate estimates are possible.  
 
4.2 Conclusion  
Models to predict days off work and days off normal activities were estimated using large patient 
datasets. These allow productivity losses associated with HRQoL to be estimated for inclusion in 
economic evaluation using a wider societal perspective. These estimates of productivity losses can 
be obtained for a dataset including the EQ-5D of patients alongside sociodemographic 
characteristics, and using the same methodology informal care need can also be estimated using the 
models reported in Rowen et al [20]. The use of large patient datasets in the estimation of the 
models reported here has the benefit that the models are based on HRQoL from a number of 
conditions. However there are a number of limitations associated with each dataset used to model 
the relationship and further research is needed to address this.  
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Figure 1: Predictions for days off paid employment  
 
 
HODaR - Health Outcomes Data Repository; HIPO - Health Improvement and Patient Outcomes; TPM  ? two part 
model; ZINB  ? zero inflated negative binomial  
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Figure 2: Predictions for days off normal activities excluding paid employment  
 
 
 
HODaR - Health Outcomes Data Repository; HIPO - Health Improvement and Patient Outcomes; TPM  ? two part 
model; ZINB  ? zero inflated negative binomial  
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Table 1: Summary of sample characteristics of HODaR and HIPO (employed and full sample) 
Sample HODAR HIPO 
 Aged < 66 , likely 
to be employed 
 Full sample 
 
Employed  Full sample 
n 27,124 55,726 1,921 6,046 
Mean EQ-5D (SD) 0.730 (0.290) 0.673 (0.311) 0.795 (0.196) 0.674 (0.287) 
Mean age (SD) 48.58 (12.13) 58.15 (17.20) 49.03 (11.88) 60.25 (16.45) 
Female 52.6% 50.3% 52.8% 50.1% 
Comorbidity 67.7% 72.8% 78.0% 84.2% 
Operation 78.2% 74.5% 89.3% 85.3% 
Length of hospital stay (SD) 3.41 (10.02) 4.54 (11.58) 1.48 (3.73) 2.35 (5.93) 
ICD Chapter     
1 Certain infectious and 
parasitic diseases  168 (0.6%) 325 (0.6%) 28 (1.4%) 69 (1.1%) 
2 Neoplasms  2,866 (10.6%) 5,795 (10.4%) 206 (12.2%) 741 (12.3%) 
3 Diseases of the blood  312 (1.2%) 757 (1.4%) 20 (1%) 141 (2.33%) 
4 Endocrine, nutritional and 
metabolic diseases 508 (1.9%) 988 (1.8%) 32 (1.7%) 104 (1.7%) 
5 Mental and behavioural 
disorders  50 (0.2%) 86 (0.2%) - - 
6 Nervous system  803 (3.0%) 1,443 (2.6%) 56 (2.9%) 174 (2.9%) 
7 Eye and adnexa  780 (2.9%) 2,938 (5.3%) 65 (3.4%) 308 (5.1%) 
8 Ear and mastoid process  174 (0.6%) 265 (0.5%) 19 (1%) 39 (0.7%) 
9 Circulatory system  3,474 (12.8%) 8,612 (15.5%) 167 (8.7%) 658 (10.9%) 
10 Respiratory system  1,048 (3.9%) 2,362 (4.2%) 75 (3.9%) 264 (4.4%) 
11 Digestive system  3,814 (14.1%) 7,393 (13.3%) 311 (16.2%) 833 (13.8%) 
12 Skin and subcutaneous 
tissue  877 (3.2%) 1,564 (2.8%) 56 (2.9%) 149 (2.5%) 
13 Musculoskeletal system  3,393 (12.5%) 6,337 (11.4%) 320 (16.7%) 826 (13.7%) 
14 Genitourinary system  2,127 (7.8%) 3,629 (6.5%) 158 (8.2%) 438 (7.2%) 
15 Pregnancy, childbirth  767 (2.8%) 1,003 (1.8%) - - 
17 Congenital malformations, 
deformations  100 (0.4%) 141 (0.3%) - - 
18 Symptoms not classified 
elsewhere 2,817 (10.4%) 6,024 (10.8%) 189 (9.8%) 613 (10.1%) 
19 Injury, poisoning and 
certain external causes 1,721 (6.3%) 3,284 (5.9%) 117 (6.1%) 343 (5.7%) 
21 Factors influencing health 
status and contact with 
health services  1,325 (4.9%) 2,780 (5.0%) 102 (5.3%) 346 (5.7%) 
Chapters 16 Certain conditions (perinatal period), 20 External causes of morbidity and mortality and 22 Codes for 
special purposes did not have any respondents 
 SD  ? standard deviation; HODaR - Health Outcomes Data Repository; HIPO - Health Improvement and Patient 
Outcomes  
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Table 2: Mean days off paid employment and normal activities  
 
Days off paid employment  
 
Days off normal activities 
 
 HODaR (6 weeks) HIPO (4 weeks) HODaR (6 weeks) HIPO (1 week) 
Mean Days Off 
(SD) 
8.50 (14.50) 9.10 (14.50) 4.80 (7.48) 1.10 (2.21) 
Mean Days Off 
Range, n(%)   
  
    0 days 16,154 (59.6%) 31,398 (56.3%) 1,083 (56.4%) 0 days   4,497 (74.4%) 
    1-7 days 3,694 (13.6%) 7,493 (13.5%) 354 (18.4%) 1 day          236 (3.9%) 
    8-14 days 1,239 (4.6%) 3,922 (7.0%) 162 (8.4%) 2 days        238 (3.9%) 
    15-21 days 914 (3.4%) 2,792 (5.0%) 287 (14.9%) 3 days         194 (3.2%) 
    22-28 days 479 (1.8%) 1,168 (2.1%) 35 (1.8%)  4 days         118 (2.0%) 
    29-35 days 1,581 (5.8%) 2,191 (3.9%) - 5 days         184 (3.0%) 
    36-41 days 163 (0.6%) 670 (1.2%) - 6 days           59 (1.0%) 
    42 days 2,900 (10.7%) 6,092 (10.9%) - 7 days         520 (8.6%) 
         
 HODaR (6 weeks) HIPO (4 weeks) HODaR (6 weeks) HIPO (1 week) 
EQ-5D range N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) 
-0.594 - 0 1215 10.1 (16.9) 9 14.0 (10.3) 3433 21.5 (18.2) 234 2.2 (3.1) 
0.001 - 0.199 1474 10.3 (16.3) 18 13.4 (8.9) 4034 16.9 (17.6) 240 2.5 (3.2) 
0.2 - 0.399 783 15.7 (18.0) 67 11.5 (9.0) 1983 19.2 (18.6) 545 2.4 (2.9) 
0.4 - 0.599 1486 10.4 (16.5) 127 8.3 (9.0) 4681 14.9 (17.0) 713 1.9 (2.7) 
0.6 - 0.799 10971 10.0 (15.3) 727 6.2 (7.9) 23298 8.1 (13.3) 2179 1.1 (2.1) 
0.8 - 0.999 2739 9.4 (14.8) 414 3.8 (6.8) 5043 6.0 (11.6) 988 0.4 (1.3) 
1 8456 4.8 (10.5) 559 1.7 (4.7) 13254 2.9 (7.7) 1147 0.2 (0.8) 
SD  ? standard deviation; HODaR - Health Outcomes Data Repository; HIPO - Health Improvement and Patient 
Outcomes  
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Table 3: Days off paid employment HODaR and HIPO (marginal effects) 
 HODaR HIPO 
 TPM  
part 1 
TPM  
part 2 
ZINB 
variable 
TPM  
part 1 
TPM  
part 2 
ZINB 
variable 
1 Certain infectious & parasitic  -0.0848 -2.324 -0.731 -0.197
*
 -1.799 -0.582 
 (0.0438) (2.211) (0.931) (0.0999) (2.567) (1.187) 
2 Neoplasms -0.157
***
 5.193
***
 2.550
***
 -0.279
***
 2.472 1.392 
 (0.0157) (1.026) (0.437) (0.0519) (1.882) (0.876) 
3 Diseases of the blood -0.0296 -4.094
*
 -1.622
*
 -0.175 -7.036
***
 -2.880
***
 
 (0.0303) (1.830) (0.776) (0.108) (1.850) (0.860) 
4 Endocrine, nutritional,  -0.0447 0.101 0.208 -0.0943 -3.461 -1.443 
metabolic (0.0252) (1.657) (0.704) (0.0886) (3.044) (1.395) 
5 Mental and behavioural  -0.0441 10.03
*
 4.281
*
    
 (0.0830) (4.525) (1.944)    
6 Nervous system -0.107
***
 2.971
*
 1.520
**
 -0.199
*
 0.346 0.337 
 (0.0218) (1.315) (0.559) (0.0785) (2.231) (1.032) 
7 Eye and adnexa -0.0514
*
 0.621 0.435 -0.102 -0.362 -0.0405 
 (0.0218) (1.431) (0.611) (0.0711) (2.717) (1.258) 
8 Ear and mastoid process -0.0723 -0.916 -0.166 -0.108 -8.274
***
 -3.435
***
 
 (0.0383) (2.237) (0.951) (0.112) (1.935) (0.877) 
9 Circulatory system -0.171
***
 5.742
***
 2.825
***
 -0.247
***
 1.489 0.933 
 (0.0156) (1.032) (0.441) (0.0543) (1.932) (0.902) 
10 Respiratory system -0.0348 -1.019 -0.307 -0.107 0.830 0.525 
 (0.0198) (1.275) (0.540) (0.0675) (2.315) (1.078) 
11 Digestive system -0.0693
***
 -0.600 -0.0139 -0.120
*
 -1.220 -0.410 
 (0.0148) (1.032) (0.440) (0.0484) (1.870) (0.871) 
12 Skin and subcutaneous tissue -0.0166 -2.864
*
 -1.180 -0.0457 -2.853 -1.277 
 (0.0202) (1.428) (0.606) (0.0753) (2.440) (1.135) 
13 Musculoskeletal system -0.159
***
 4.925
***
 2.463
***
 -0.203
***
 1.848 1.077 
 (0.0152) (0.998) (0.426) (0.0495) (1.802) (0.839) 
14 Genitourinary system -0.0800
***
 -1.848 -0.540 -0.155
**
 -0.470 -0.00886 
 (0.0162) (1.083) (0.460) (0.0549) (1.919) (0.893) 
15 Pregnancy, childbirth 0.00601 0.691 0.275    
 (0.0202) (1.556) (0.657)    
17 Congenital mal/deformations -0.160
**
 4.842 2.455
*
    
 (0.0497) (2.692) (1.153)    
18 Symptoms not classified  -0.0516
**
 -2.963
**
 -1.088
*
 -0.0684 -2.059 -0.895 
elsewhere (0.0157) (1.068) (0.453) (0.0531) (1.971) (0.916) 
19 Injury, poisoning, external -0.213
***
 4.940
***
 2.526
***
 -0.305
***
 2.478 1.416 
 (0.0175) (1.057) (0.451) (0.0610) (1.913) (0.891) 
EQ-5D  0.0727
***
 -14.67
***
 -8.109
***
 0.754
***
 -7.278
***
 -11.54
***
 
 (0.0114) (0.607) (0.340) (0.0616) (1.212) (0.780) 
Age/10 -0.359
***
 6.216
***
 9.736
***
 -0.0312 4.137
*
 2.130
*
 
 (0.0188) (1.217) (0.623) (0.0561) (1.639) (0.846) 
Age/10 squared 0.0501
***
 -0.525
***
 -1.213
***
 0.00493 -0.436
*
 -0.240
**
 
 (0.00206) (0.136) (0.0689) (0.00601) (0.179) (0.0905) 
female 0.0107 -1.046
**
 -0.856
***
 -0.0811
***
 -0.486 0.536 
 (0.00657) (0.380) (0.205) (0.0216) (0.563) (0.311) 
comorbid -0.0401
***
 4.580
***
 1.977
***
 -0.0602
*
 -0.185 0.00976 
 (0.00687) (0.445) (0.187) (0.0266) (0.754) (0.345) 
operation 0.0311
***
 -0.116 -0.153 -0.0537 1.610 0.750 
 (0.00785) (0.459) (0.192) (0.0358) (1.112) (0.504) 
N 27124 10970 27124 1921 838 1921 
Standard errors in parentheses  * p<0.1; ** p<0.05; *** p<0.01 
HODaR - Health Outcomes Data Repository; HIPO - Health Improvement and Patient Outcomes; TPM  ? two part 
model; ZINB  ? zero inflated negative binomial  
1-19  ? has condition in ICD chapter; Age/10  ? age divided by 10; Comorbid  ? has comorbidity; Operation - has had an 
operation  
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Table 4: Days off normal activities HODaR and HIPO (marginal effects) 
 HODaR HIPO 
 TPM  
part 1 
TPM  
part 2 
ZINB 
variable 
TPM  
part 1 
TPM  
part 2 
ZINB 
variable 
1 Certain infectious & parasitic  -0.117
***
 1.053 -0.731 0.0221 -0.284 -0.0838 
 (0.0331) (1.484) (0.931) (0.0516) (0.533) (0.147) 
2 Neoplasms -0.117
***
 4.341
***
 2.550
***
 -0.0334 0.292 0.0862 
 (0.0111) (0.620) (0.437) (0.0267) (0.319) (0.0859) 
3 Diseases of the blood -0.0315 0.103 -1.622
*
 0.0357 -0.726 -0.204 
 (0.0202) (1.171) (0.776) (0.0389) (0.457) (0.126) 
4 Endocrine, nutritional,  -0.0421
*
 0.798 0.208 0.0477 -0.731 -0.225 
metabolic (0.0188) (1.038) (0.704) (0.0413) (0.493) (0.138) 
5 Mental and behavioural  0.0459 -2.624 4.281
*
    
 (0.0518) (2.733) (1.944)    
6 Nervous system -0.104
***
 2.300
**
 1.520
**
 -0.0453 -0.280 -0.0680 
 (0.0163) (0.806) (0.559) (0.0380) (0.362) (0.0963) 
7 Eye and adnexa -0.00102 -2.008
**
 0.435 0.00633 -0.493 -0.138 
 (0.0128) (0.745) (0.611) (0.0325) (0.428) (0.116) 
8 Ear and mastoid process 0.00802 -1.941 -0.166 0.00578 -0.436 -0.127 
 (0.0302) (2.130) (0.951) (0.0614) (0.591) (0.155) 
9 Circulatory system -0.143
***
 4.314
***
 2.825
***
 -0.0680
*
 0.276 0.0845 
 (0.0109) (0.602) (0.441) (0.0278) (0.312) (0.0839) 
10 Respiratory system -0.0592
***
 2.146
**
 -0.307 -0.0306 0.127 0.0421 
 (0.0145) (0.765) (0.540) (0.0344) (0.393) (0.106) 
11 Digestive system -0.0630
***
 0.438 -0.0139 -0.00419 -0.532 -0.142 
 (0.0107) (0.611) (0.440) (0.0258) (0.305) (0.0822) 
12 Skin and subcutaneous tissue -0.0227 -0.388 -1.180 0.0529 -0.326 -0.116 
 (0.0154) (0.917) (0.606) (0.0381) (0.526) (0.146) 
13 Musculoskeletal system -0.196
***
 5.544
***
 2.463
***
 -0.0776
**
 0.392 0.117 
 (0.0111) (0.582) (0.426) (0.0265) (0.289) (0.0776) 
14 Genitourinary system -0.0754
***
 0.326 -0.540 -0.0234 0.00496 0.00905 
 (0.0121) (0.682) (0.460) (0.0292) (0.351) (0.0945) 
15 Pregnancy, childbirth 0.00310 -3.206
**
 0.275    
 (0.0172) (1.054) (0.657)    
17 Congenital mal/deformations -0.129
**
 6.763
**
 2.455
*
    
 (0.0426) (2.370) (1.153)    
18 Symptoms not classified  -0.0504
***
 -1.107 -1.088
*
 -0.0319 -0.219 -0.0510 
elsewhere (0.0112) (0.622) (0.453) (0.0278) (0.315) (0.0847) 
19 Injury, poisoning, external -0.185
***
 8.553
***
 2.526
***
 -0.0497 0.549 0.156 
 (0.0127) (0.651) (0.451) (0.0315) (0.329) (0.0883) 
EQ-5D  0.427
***
 -16.03
***
 -8.109
***
 0.382
***
 -3.322
***
 -2.358
***
 
 (0.00737) (0.323) (0.340) (0.0176) (0.165) (0.0903) 
Age/10 -0.0439
***
 2.446
***
 9.736
***
 -0.0723
***
 0.0674 0.0855 
 (0.00775) (0.417) (0.623) (0.0186) (0.234) (0.0522) 
Age/10 squared 0.00701
***
 -0.159
***
 -1.213
***
 0.0102
***
 0.00352 0.0207 
 (0.000702) (0.0371) (0.0689) (0.00165) (0.0202) (0.0467) 
female -0.0453
***
 -1.961
***
 -0.856
***
 -0.0313
**
 -0.151 0.377
***
 
 (0.00465) (0.236) (0.205) (0.0106) (0.116) (0.0946) 
comorbid -0.0416
***
 3.558
***
 1.977
***
 -0.00853 0.312 -0.0471
***
 
 (0.00509) (0.292) (0.187) (0.0151) (0.196) (0.00844) 
operation 0.00296 0.540
*
 -0.153 -0.0430
**
 0.0542 0.0970 
 (0.00536) (0.271) (0.192) (0.0165) (0.174) (0.0523) 
N 55726 24328 55726 6046 1549 6046 
Standard errors in parentheses * p<0.1; ** p<0.05; *** p<0.01 
HODaR - Health Outcomes Data Repository; HIPO - Health Improvement and Patient Outcomes; TPM  ? two part 
model; ZINB  ? zero inflated negative binomial  
1-19  ? has condition in ICD chapter; Age/10  ? age divided by 10; Comorbid  ? has a comorbidity; Operation - has had an 
operation
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APPENDIX 
Table 5: Days off paid employment HODaR and HIPO 
 HODaR (6 weeks recall period) HIPO ( 4 weeks recall period) 
 TPM part 
1 
TPM Part 
2 
ZINB 
variable 
TPM part 
1 
TPM part 
2 
ZINB 
variable 
1 Certain infectious and parasitic -0.245** -0.138 -0.105 -0.586** -0.203 -0.147 
 (0.122) (0.138) (0.138) (0.287) (0.295) (0.303) 
2 Neoplasms -0.442*** 0.253*** 0.297*** -0.813*** 0.225 0.283 
 (0.046) (0.054) (0.056) (0.163) (0.186) (0.199) 
3 Diseases of the blood -0.088 -0.257** -0.249* -0.526* -1.262*** -1.129*** 
 (0.089) (0.124) (0.128) (0.310) (0.296) (0.282) 
4 Endocrine, nutritional, -0.132* 0.006 0.028 -0.295 -0.435 -0.414 
 (0.073) (0.092) (0.094) (0.270) (0.432) (0.446) 
5 Mental and behavioural -0.130 0.442*** 0.458*** - - - 
 (0.239) (0.166) (0.172)    
6 Nervous system -0.307*** 0.153** 0.188*** -0.592** 0.035 0.076 
 (0.062) (0.068) (0.069) (0.231) (0.224) (0.235) 
7 Eye and adnexa -0.151** 0.034 0.057 -0.318 -0.038 -0.010 
 (0.063) (0.078) (0.080) (0.219) (0.283) (0.297) 
8 Ear and mastoid process -0.210* -0.052 -0.023 -0.335 -1.853*** -1.644*** 
 (0.108) (0.130) (0.132) (0.333) (0.595) (0.448) 
9 Circulatory system -0.479*** 0.276*** 0.325*** -0.724*** 0.141 0.198 
 (0.045) (0.055) (0.057) (0.169) (0.192) (0.205) 
10 Respiratory system -0.103* -0.058 -0.043 -0.332 0.081 0.116 
 (0.059) (0.073) (0.075) (0.209) (0.228) (0.241) 
11 Digestive system -0.202*** -0.034 -0.002 -0.370** -0.133 -0.101 
 (0.044) (0.058) (0.060) (0.157) (0.195) (0.208) 
12 Skin and subcutaneous tissue -0.050 -0.173* -0.175* -0.148 -0.344 -0.357 
 (0.061) (0.088) (0.092) (0.241) (0.303) (0.328) 
13 Musculoskeletal system -0.446*** 0.241*** 0.288*** -0.603*** 0.173 0.226 
 (0.044) (0.054) (0.056) (0.157) (0.181) (0.194) 
14 Genitourinary system -0.232*** -0.108* -0.076 -0.471*** -0.049 -0.002 
 (0.047) (0.062) (0.064) (0.172) (0.197) (0.210) 
15 Pregnancy, childbirth 0.018 0.038 0.037 - - - 
 (0.062) (0.084) (0.087)    
17 Congenital mal/deformations -0.448*** 0.238* 0.288** - - - 
 (0.134) (0.122) (0.122)    
18 Symptoms not classified -0.152*** -0.180*** -0.160** -0.218 -0.235 -0.236 
 (0.047) (0.063) (0.064) (0.172) (0.214) (0.229) 
19 Injury, poisoning, external -0.590*** 0.242*** 0.295*** -0.884*** 0.225 0.287 
 (0.050) (0.056) (0.058) (0.185) (0.189) (0.201) 
EQ-5D  0.201*** -0.724*** -0.746*** 2.192*** -0.699*** -0.674*** 
 (0.032) (0.029) (0.031) (0.201) (0.117) (0.123) 
Age/10 -0.996*** 0.307*** 0.282*** -0.091 0.397** 0.392** 
 (0.053) (0.060) (0.060) (0.163) (0.157) (0.162) 
Age/10 squared 0.139*** -0.026*** -0.023*** 0.014 -0.042** -0.042** 
 (0.006) (0.007) (0.007) (0.017) (0.017) (0.018) 
female 0.030 -0.052*** -0.041** -0.236*** -0.047 -0.045 
 (0.018) (0.019) (0.019) (0.063) (0.054) (0.055) 
comorbid -0.111*** 0.226*** 0.236*** -0.175** -0.018 0.002 
 (0.019) (0.022) (0.022) (0.078) (0.072) (0.075) 
operation 0.086*** -0.006 -0.018 -0.156 0.155 0.163 
 (0.022) (0.023) (0.023) (0.104) (0.107) (0.110) 
Constant 1.761*** 2.423*** 2.444*** -0.597 1.788*** 1.712*** 
 (0.125) (0.144) (0.145) (0.450) (0.420) (0.433) 
Inflated Variables   ࢽෝ   ࢽෝ 
EQ5D   0.412***   4.216*** 
   (0.051)   (0.397) 
Age/10   -1.635***   -0.165 
   (0.089)   (0.286) 
Age/10 squared   0.226***   0.024 
   (0.010)   (0.031) 
Female   0.115***   -0.371*** 
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 HODaR (6 weeks recall period) HIPO ( 4 weeks recall period) 
 TPM part 
1 
TPM Part 
2 
ZINB 
variable 
TPM part 
1 
TPM part 
2 
ZINB 
variable 
   (0.030)   (0.106) 
Constant   2.234***   -2.811*** 
   (0.194)   (0.723) 
Dispersion   0.946 0.966  0.562 0.584 
       
N 27,124 10,970 27,124 1,921 838 1,921 
Log likelihood -17141 -43518 -60906 -1158 -2725 -3915 
AIC 34333 87088 121875 2360 5497 7886 
BIC 34538 87277 122129 2483 5606 8041 
Standard errors in parentheses 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
HODaR - Health Outcomes Data Repository; HIPO - Health Improvement and Patient Outcomes; TPM  ? two part model; 
ZINBv  ? zero inflated negative binomial with variable inflation 
1-19  ? has condition in ICD chapter; Age/10  ? age divided by 10; Comorbid  ? has comorbidity; Operation - has had an 
operation   
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Table 6: Days off normal activities HODaR and HIPO 
 HODaR (6 weeks recall period) HIPO (1 week recall period) 
 TPM  
part 1 
TPM  
part 2 
ZINB 
variable 
TPM  
part 1 
TPM  
part 2 
ZINB 
variable 
1 Certain infectious and parasitic -0.328*** 0.058 0.071 0.087 -0.071 -0.080 
 (0.091) (0.080) (0.079) (0.201) (0.135) (0.142) 
2 Neoplasms -0.328*** 0.219*** 0.234*** -0.115 0.073 0.080 
 (0.032) (0.033) (0.034) (0.096) (0.075) (0.076) 
3 Diseases of the blood -0.092 0.006 0.011 0.139 -0.191 -0.204 
 (0.058) (0.066) (0.067) (0.155) (0.126) (0.132) 
4 Endocrine, nutritional, metabolic -0.122** 0.044 0.049 0.191 -0.193 -0.228 
 (0.054) (0.057) (0.057) (0.171) (0.137) (0.149) 
5 Mental and behavioural disorders 0.140 -0.160 -0.178 - - - 
 (0.163) (0.180) (0.186)    
6 Nervous system -0.293*** 0.122*** 0.136*** -0.159 -0.070 -0.064 
 (0.046) (0.043) (0.043) (0.132) (0.090) (0.090) 
7 Eye and adnexa -0.003 -0.120*** -0.126*** 0.024 -0.126 -0.134 
 (0.038) (0.045) (0.046) (0.122) (0.112) (0.115) 
8 Ear and mastoid process 0.024 -0.116 -0.126 0.022 -0.111 -0.122 
 (0.090) (0.134) (0.139) (0.231) (0.155) (0.155) 
9 Circulatory system -0.399*** 0.218*** 0.234*** -0.234** 0.064 0.074 
 (0.031) (0.033) (0.033) (0.098) (0.073) (0.074) 
10 Respiratory system -0.170*** 0.114*** 0.123*** -0.107 0.029 0.037 
 (0.041) (0.041) (0.041) (0.122) (0.093) (0.094) 
11 Digestive system -0.181*** 0.024 0.034 -0.019 -0.141* -0.142* 
 (0.031) (0.034) (0.035) (0.095) (0.076) (0.078) 
12 Skin and subcutaneous tissue -0.066 -0.022 -0.022 0.213 -0.082 -0.111 
 (0.045) (0.052) (0.053) (0.159) (0.134) (0.145) 
13 Musculoskeletal system -0.543*** 0.272*** 0.291*** - 0.090 0.101 
 (0.032) (0.031) (0.032) (0.094) (0.068) (0.069) 
14 Genitourinary system -0.215*** 0.018 0.030 -0.084 0.001 0.008 
 (0.035) (0.038) (0.039) (0.106) (0.084) (0.085) 
15 Pregnancy, childbirth 0.009 -0.200*** -0.214*** - - - 
 (0.051) (0.070) (0.071)    
17 Congenital mal/deformations -0.361*** 0.323*** 0.338*** - - - 
 (0.116) (0.099) (0.099)    
18 Symptoms not classified -0.145*** -0.065* -0.058 -0.112 -0.054 -0.048 
 (0.033) (0.036) (0.036) (0.100) (0.077) (0.078) 
19 Injury, poisoning, external -0.512*** 0.394*** 0.410*** -0.173 0.123 0.132* 
 (0.036) (0.033) (0.033) (0.111) (0.076) (0.076) 
EQ-5D  1.198*** -0.779*** -0.780*** 1.331*** - -0.816*** 
 (0.023) (0.015) (0.016) (0.067) (0.043) (0.046) 
Age/10 -0.123*** 0.119*** 0.178*** - 0.016 0.013 
 (0.022) (0.020) (0.014) (0.065) (0.056) (0.056) 
Age/10 squared 0.020*** -0.008*** 0.024* 0.036*** 0.001 0.001 
 (0.002) (0.002) (0.013) (0.006) (0.005) (0.005) 
female -0.127*** -0.095*** 0.116*** - -0.036 -0.033 
 (0.013) (0.011) (0.020) (0.037) (0.028) (0.028) 
comorbid -0.117*** 0.173*** -0.008*** -0.030 0.074 0.076 
 (0.014) (0.014) (0.002) (0.053) (0.047) (0.047) 
operation 0.008 0.026** -0.094*** -0.144** 0.012 0.017 
 (0.015) (0.013) (0.011) (0.058) (0.041) (0.042) 
Constant -0.237*** 2.772*** 2.764*** 0.269 1.656*** 1.661*** 
 (0.067) (0.063) (0.064) (0.217) (0.179) (0.179) 
Inflation variables       
EQ5D   2.110***   2.130*** 
   (0.041)   (0.114) 
Age/10   -0.286***   -0.533*** 
   (0.035)   (0.113) 
Age/10 squared   0.040***   0.071*** 
   (0.003)   (0.010) 
female   -0.175***   -0.196*** 
   (0.021)   (0.064) 
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 HODaR (6 weeks recall period) HIPO (1 week recall period) 
 TPM  
part 1 
TPM  
part 2 
ZINB 
variable 
TPM  
part 1 
TPM  
part 2 
ZINB 
variable 
Constant   -0.919***   0.237 
   (0.099)   (0.322) 
Dispersion  0.653 0.659  0.0233 0.0255 
       
N 55,726 24,328 55,726 6,046 1,549 6,046 
Log likelihood -34,794 -95,635 -130,924 -3,088 -3,280 -6,557 
AIC 69,638 191,322 261,909 6,219 6,605 12,841 
BIC 69,861 191,533 262,186 6,367 6,728 13,028 
 
Standard errors in parentheses 
*
 p < 0.05, 
**
 p < 0.01, 
***
 p < 0.001 
HODaR - Health Outcomes Data Repository; HIPO - Health Improvement and Patient Outcomes; TPM  ? two part model; 
ZINBv  ? zero inflated negative binomial with variable inflation 
1-19  ? has condition in ICD chapter; Age/10  ? age divided by 10; Comorbid  ? has comorbidity; Operation - has had an 
operation 
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Table 7: Coefficients for TPM to allow predictions of days off work or days off normal activities 
Days off work     
 HODaR  HIPO  
 TPM part1 TPM part 2 TPM part1 TPM part 2 
1 Certain infectious and parasitic diseases -0.24508431 -0.13794693 -0.58587641 -0.20253513 
2 Neoplasms -0.44196263 0.25308716 -0.81296505 0.22469750 
3 Diseases of the blood -0.08807063 -0.25748607 -0.52603158 -1.26238533 
4 Endocrine, nutritional, metabolic -0.13206202 0.00558699 -0.29546461 -0.43493427 
5 Mental and behavioural disorders -0.13034625 0.44228184   
6 Nervous system -0.30730500 0.15250512 -0.59230927 0.03465576 
7 Eye and adnexa -0.15103577 0.03384859 -0.31789851 -0.03754577 
8 Ear and mastoid process -0.21015407 -0.05212614 -0.33488613 -1.85272609 
9 Circulatory system -0.47895778 0.27642237 -0.72430845 0.14129737 
10 Respiratory system -0.10321344 -0.05817031 -0.33164145 0.08123540 
11 Digestive system -0.20176801 -0.03383309 -0.37004283 -0.13277972 
12 Skin and subcutaneous tissue -0.04998003 -0.17296831 -0.14823411 -0.34358400 
13 Musculoskeletal system -0.44638718 0.24146286 -0.60301682 0.17255406 
14 Genitourinary system -0.23188857 -0.10809127 -0.47079657 -0.04903272 
15 Pregnancy, childbirth 0.01834339 0.03760131   
17 Congenital mal/deformations -0.44835238 0.23782896   
18 Symptoms not classified elsewhere -0.15175235 -0.17950138 -0.21796800 -0.23547081 
19 Injury, poisoning, external -0.59014383 0.24214064 -0.88363333 0.22518297 
EQ-5D  0.20144421 -0.72436821 2.19197953 -0.69924506 
Age/10 -0.99626379 0.30698379 -0.09071621 0.39742346 
Age/10 squared 0.13875395 -0.02592483 0.01434990 -0.04191095 
Female 0.02977747 -0.05165029 -0.23574510 -0.04672291 
Comorbidity -0.11123936 0.22619982 -0.17513219 -0.01780249 
Operation 0.08624032 -0.00571200 -0.15610999 0.15467928 
Constant 1.76077781 2.42285513 -0.59688067 1.78829541 
ŝƐƉĞƌƐŝŽŶ ?ɲ ?  0.9462932  0.5623412 
     
Days off Normal Activities     
1 Certain infectious and parasitic diseases -0.32786713 0.05771232 0.08670380 -0.07367897 
2 Neoplasms -0.32811405 0.21903631 -0.11926633 0.06786809 
3 Diseases of the blood -0.09161548 0.00579628 0.13934071 -0.19125374 
4 Endocrine, nutritional, metabolic -0.12176296 0.04401712 0.19116868 -0.19355829 
5 Mental and behavioural disorders 0.13992641 -0.16020950   
6 Nervous system -0.29333664 0.12197855 -0.15925119 -0.06977515 
7 Eye and adnexa -0.00300514 -0.12024362 0.02364103 -0.12567657 
8 Ear and mastoid process 0.02383457 -0.11594762 0.02215244 -0.11058757 
9 Circulatory system -0.39850584 0.21781476 -0.23382296 0.06382162 
10 Respiratory system -0.17005568 0.11427064 -0.10745245 0.02782909 
11 Digestive system -0.18071168 0.02441086 -0.01451493 -0.13671081 
12 Skin and subcutaneous tissue -0.06631625 -0.02215379 0.21341741 -0.08204150 
13 Musculoskeletal system -0.54254914 0.27213061 -0.26457574 0.08992269 
14 Genitourinary system -0.21496289 0.01824900 -0.08410712 0.00051135 
15 Pregnancy, childbirth 0.00919058 -0.19952601   
17 Congenital mal/deformations -0.36127705 0.32319440   
18 Symptoms not classified elsewhere -0.14522172 -0.06450461 -0.11327288 -0.05542834 
19 Injury, poisoning, external -0.51218389 0.39371337 -0.17335731 0.12320991 
EQ-5D  1.19834117 -0.77909880 1.33120016 -0.78713305 
Age/10 -0.12319003 0.11890256 -0.25319571 0.01639363 
Age/10 squared 0.01965632 -0.00771880 0.03565989 0.00079459 
Female -0.12712540 -0.09531266 -0.10921793 -0.03583822 
Comorbidity -0.11663993 0.17295911 -0.02939702 0.07354753 
Operation 0.00829142 0.02625400 -0.14470939 0.00783676 
Constant -0.23710103 2.77182424 0.26886470 1.65875542 
ŝƐƉĞƌƐŝŽŶ ?ɲ ?  0.6528781  0.0233346 
 
